Armstrong Advisory Group Inc. Acquires 200 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Armstrong Advisory Group Inc. grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 14.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,606 shares of the biopharmaceutical company’s stock after acquiring an additional 200 shares during the quarter. Armstrong Advisory Group Inc.’s holdings in Gilead Sciences were worth $148,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Park Avenue Securities LLC lifted its stake in shares of Gilead Sciences by 31.4% in the 4th quarter. Park Avenue Securities LLC now owns 28,753 shares of the biopharmaceutical company’s stock valued at $2,656,000 after acquiring an additional 6,878 shares during the last quarter. Kathmere Capital Management LLC increased its holdings in Gilead Sciences by 42.7% in the 4th quarter. Kathmere Capital Management LLC now owns 17,527 shares of the biopharmaceutical company’s stock worth $1,619,000 after purchasing an additional 5,246 shares in the last quarter. San Luis Wealth Advisors LLC raised its position in Gilead Sciences by 3.3% in the fourth quarter. San Luis Wealth Advisors LLC now owns 9,885 shares of the biopharmaceutical company’s stock valued at $913,000 after purchasing an additional 319 shares during the last quarter. Accurate Wealth Management LLC boosted its stake in shares of Gilead Sciences by 7.1% during the fourth quarter. Accurate Wealth Management LLC now owns 3,456 shares of the biopharmaceutical company’s stock valued at $311,000 after purchasing an additional 230 shares in the last quarter. Finally, 180 Wealth Advisors LLC grew its holdings in shares of Gilead Sciences by 81.1% during the fourth quarter. 180 Wealth Advisors LLC now owns 10,990 shares of the biopharmaceutical company’s stock worth $1,015,000 after purchasing an additional 4,920 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the topic of several recent research reports. Leerink Partners upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $74.00 to $96.00 in a research report on Monday, October 21st. Oppenheimer boosted their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. Cantor Fitzgerald restated a “neutral” rating and issued a $80.00 price objective on shares of Gilead Sciences in a report on Wednesday, December 11th. Maxim Group downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Finally, Wells Fargo & Company increased their price target on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Eleven analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $97.96.

Insider Transactions at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 6,788 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the transaction, the director now directly owns 8,920 shares of the company’s stock, valued at $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the sale, the chief financial officer now owns 129,873 shares in the company, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 456,234 shares of company stock worth $42,130,461 in the last quarter. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Down 0.8 %

Shares of NASDAQ GILD opened at $91.65 on Friday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The company has a 50-day moving average price of $91.97 and a 200-day moving average price of $83.76. The stock has a market capitalization of $114.22 billion, a P/E ratio of 1,018.33, a P/E/G ratio of 1.27 and a beta of 0.18. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $98.90.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. During the same period in the previous year, the company posted $2.29 EPS. The company’s revenue for the quarter was up 7.0% on a year-over-year basis. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 3.36%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s dividend payout ratio is 3,422.22%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.